Assessment of Geriatric Evaluations Impact on New AML Guidance
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza ostrej białaczki szpikowej (AML)
- •Pacjent jest brany pod uwagę do rozpoczęcia nowego leczenia
- •Wiek 50 lat lub więcej
- •Ogólny stan zdrowia pozwala na uczestnictwo w badaniu (kategorie 0, 1 lub 2)
✗ Disqualifies
- •Niemożność zrozumienia lub podpisania świadomej zgody na udział w badaniu
- •Niemożność samodzielnego wypełniania kwestionariuszy lub brak osoby pomagającej w ich uzupełnieniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 50 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Locations (1)
Abramson Cancer Center at University of Pennsylvania
Philadelphia, United States
Trial contact
Colleen Redlinger
Catherine Lai, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.